Log In
BCIQ
Print this Print this
 

hypericin (HBP-347, SGX301)

  Manage Alerts
Collapse Summary General Information
Company Soligenix Inc.
DescriptionTopical phototherapeutic agent that inhibits heat shock protein 90 (Hsp90)
Molecular Target Heat shock protein 90 (Hsp90)
Mechanism of ActionHsp90 inhibitor
Therapeutic ModalityMedical Devices: Photodynamic therapy
Latest Stage of DevelopmentPhase III
Standard IndicationCutaneous T cell lymphoma (CTCL)
Indication DetailsTreat cutaneous T cell lymphoma (CTCL)
Regulatory Designation U.S. - Fast Track (Treat cutaneous T cell lymphoma (CTCL));
U.S. - Orphan Drug (Treat cutaneous T cell lymphoma (CTCL));
EU - Orphan Drug (Treat cutaneous T cell lymphoma (CTCL))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$14.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/05/2014

$14.0M

Undisclosed

Undisclosed

Get a free BioCentury trial today